Associate Principal Statistical Analyst
Revolution Medicines
Summary
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.
Job description
The Opportunity
- Provide Statistical Programming support in production or verification of SAS scripts and outputs for analysis files, tables, listings, figures, and other clinical trial deliverables, plus writing analysis file specifications and documentation of deliverables and analysis methods.
- Ensure effective planning to meet quality and timely delivery of deliverables.
- Comply with project/study programming standards and specifications following internal guidelines.
- Ensure accuracy of clinical trial results for internal and external audiences via biometrics QC of documents with clinical data.
- Programming support for deliverables such as Investigator Brochures, publications, US and ex-US regulatory submissions, including CDISC compliant datasets (SDTM, ADaM) and data documentation, Reviewer's Guide, TLFs, and Statistical Analysis Plans (study specific, ISS, ISE, Exposure-Response).
- Hands-on programming of in-house deliverables including Dose Committee meetings, Board of Director meetings, and Exploratory Analysis; verification review of Statistical Analysis Plans, documents, spreadsheets, and slides for in-house presentations and external publications.
Required Skills, Experience and Education
- Master's degree or equivalent in Computer Science, Mathematics, Bioinformatics or related.
- Ten (10) years of statistical programming experience with clinical trial data using SAS software.
- Eight (8) years of SAS programming experience.
- Experience supporting at least 2 studies end-to-end with 100% of deliverables coded/quality controlled without major findings.
- Experience supporting at least 2 studies where CDISC datasets were delivered.
- Experience preparing Define-XML/ADRG and reducing Pinnacle 21 validation issues.
- Experience supporting successful Phase I-III studies, with participation in at least two of: New Drug Application, Biologics License Application, and/or Marketing Authorization Application.
- Experience leading direct reports or study teams with on-time delivery rate of at least 95% and including budget or resource allocation across 2 studies.
- Experience developing macros/tools with reduction in programming cycle time and improved quality control efficiency.
- Successful completion of background checks and employment history verification required.
- Hybrid work arrangement; employee must reside in the San Francisco Bay area and may work remotely three (3) days per week.
Requirements
- Master's degree or equivalent in Computer Science, Mathematics, Bioinformatics or related
- Ten (10) years of statistical programming experience with clinical trial data using SAS software
- Eight (8) years of SAS programming experience
- Experience supporting at least 2 studies end-to-end with 100% of deliverables coded/quality controlled without major findings
- Experience supporting at least 2 studies where CDISC datasets were delivered
- Experience preparing Define-XML/ADRG and reducing Pinnacle 21 validation issues
- Experience supporting successful Phase I-III studies with participation in at least two of NDA, BLA, and/or MAA
- Experience leading direct reports or study teams with at least 95% on-time delivery and budget or resource allocation across 2 studies
- Experience developing macros/tools with reduced programming cycle time and improved quality control efficiency
- Successful completion of background checks and employment history verification
- Must reside in the San Francisco Bay area
Benefits
- Competitive Cash Compensation
- Equity Awards
- Health Benefits
- Learning & Development
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.